肺癌是全球死亡率最高的癌症之一，非小细胞肺癌占肺癌总人群的85%以上。约2/3的非小细胞肺癌患者在诊断时已为晚期，内科治疗是晚期非小细胞肺癌患者的主要治疗手段。近些年随着靶向治疗药物表皮生长因子受体–酪氨酸激酶抑制剂（EGFR-TKI）分子治疗的出现，非小细胞肺癌患者的治疗取得了明显的成效。但是EGFR-TKI耐药问题也接踵而至，总结了非小细胞肺癌患者EGFR-TKI治疗进展以及耐药后的治疗策略，为临床选择适合患者个体化治疗方案提供参考。

Lung cancer is one of the most lethal cancers in the world. Of them, non-small cell lung cancer (NSCLC) accounts for more than 85% of the total population in China. Almost 2/3 of NSCLC patients are in advanced stage at the time of diagnosis, and medical treatment is the primary/main options for patients with advanced NSCLC. Recently, with the emergence of molecular therapy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), the treatment of NSCLC has achieved remarkable progression. However, the problem of EGFR-TKI resistance is also coming. This review will summarize the treatment progress of EGFR-TKI in patients with NSCLC and the therapeutic strategies after drug resistance, so as to provide reference for clinical selection of patients with individualized treatment.

R979.1